Henze G, Langermann H J, Kaufmann U, Ludwig R, Schellong G, Stollmann B, Riehm H
Am J Pediatr Hematol Oncol. 1981 Winter;3(4):369-76.
From 1970 to 1977, two nonrandomized groups of children with acute lymphoblastic leukemia (ALL) were treated with two different induction regimens. A total of 168 patients (group DAL) received induction therapy closely adapted to St. Jude protocol VII. A total of 119 patients (group BFM) were treated with the West Berlin induction protocol. Evaluable for analysis were 138 patients of group DAL and 113 patients of group BFM. Thirty children had thymic involvement (Thy+), 15 in each group. In children without thymic involvement (Thy+), the median initial white blood count (WBC) was 8400/mm3 in group DAL and 8000/mm3 in group BFM. In contrast, the initial WBC was 42,000/mm3 and 79,200/mm3 in the corresponding group with thymic involvement (Thy+). The probability of continuous complete remission (CCR) at 9 years is 0.41 +/- 0.05 for patients without thymic involvement and 0.09 +/- 0.09 for patients with thymic involvement in group DAL, and 0.65 +/- 0.05 for those without thymic involvement and 0.52 +/- 0.13 for those who had thymic involvement in group BFM. After adjustment for initial WBC (regression analysis) the presence of thymic involvement was still a predictor of poor outcome in group DAL (p less than 0.001), whereas it was not a predictor of poor response in group BFM. In view of comparable patient composition in both treatment groups, the favorable prognosis in BFM patients has to be related to the mode of induction therapy.
1970年至1977年期间,两组非随机分组的急性淋巴细胞白血病(ALL)患儿接受了两种不同的诱导治疗方案。共有168例患者(DAL组)接受了与圣裘德方案VII紧密适配的诱导治疗。共有119例患者(BFM组)接受了西柏林诱导方案治疗。可进行分析评估的有DAL组的138例患者和BFM组的113例患者。30名儿童有胸腺受累(Thy+),每组各15例。在无胸腺受累(Thy+)的儿童中,DAL组的初始白细胞计数(WBC)中位数为8400/mm³,BFM组为8000/mm³。相比之下,在相应的有胸腺受累(Thy+)组中,初始WBC分别为42,000/mm³和79,200/mm³。DAL组中,无胸腺受累患者9年持续完全缓解(CCR)的概率为0.41±0.05,有胸腺受累患者为0.09±0.09;BFM组中,无胸腺受累患者为0.65±0.05,有胸腺受累患者为0.52±0.13。在对初始WBC进行校正(回归分析)后,胸腺受累在DAL组中仍是预后不良的预测因素(p<0.001),而在BFM组中并非预后不良的预测因素。鉴于两个治疗组的患者构成具有可比性,BFM组患者预后良好必定与诱导治疗方式有关。